Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
34.8M
-
Shares change
-
+988K
-
Total reported value, excl. options
-
$1.02B
-
Value change
-
+$28.9M
-
Number of buys
-
39
-
Number of sells
-
-14
-
Price
-
$29.30
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q3 2020
65 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q3 2020.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.8M shares
of 120M outstanding shares and own 28.94% of the company stock.
Largest 10 shareholders include FRAZIER MANAGEMENT LLC (10.5M shares), FMR LLC (5.73M shares), ORBIMED ADVISORS LLC (4.67M shares), Bain Capital Life Sciences Investors, LLC (3.98M shares), BlackRock Inc. (2.06M shares), RA CAPITAL MANAGEMENT, L.P. (1.17M shares), Vivo Capital, LLC (1.11M shares), PRICE T ROWE ASSOCIATES INC /MD/ (991K shares), VANGUARD GROUP INC (857K shares), and Omega Fund Management, LLC (659K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.